Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Bedside CSF Monitor Detects Early Infection in Fluid Drains

By LabMedica International staff writers
Posted on 04 Jun 2026

External drainage of cerebrospinal fluid (CSF) after traumatic brain injury, hydrocephalus, or hemorrhage carries a significant risk of infection. More...

These infections can prolong intensive care, cause severe meningitis and neurological injury, and increase mortality. Detection today relies on intermittent laboratory testing of fluid samples, which can miss early changes. To help address this gap, researchers have now developed a bedside system that continuously monitors CSF drain output for early signs of infection and flow problems.

Called NeuroSense, the monitoring platform was developed by an international team led by the University of Waterloo (Ontario, Canada). It is intended to save lives and reduce health-care costs in brain-injury care by enabling earlier identification of complications in intensive care units. The study reporting the technology was published in Science Translational Medicine.

NeuroSense connects inline to standard drainage tubing to analyze CSF in near real time. A 3D-printed device about the size of a smartphone houses four sensors that feed an electrochemical analyzer and a bedside display. The system tracks infection-associated biomarkers, including glucose, lactate, and pH, as well as flow rate, allowing staff to follow trends rather than wait for periodic lab results.

The clinical burden is substantial. In the United States, about 25,000 hospitalized patients each year require drains to remove excess brain fluid following traumatic brain injury or conditions such as hydrocephalus and brain hemorrhage. Up to 20% of these cases develop infections, which can more than double hospital length of stay and lead to severe meningitis, neural damage, disability, or death. Current detection relies on manual sampling sent to laboratories, a labor-intensive process typically performed only once every day or two.

Initial evaluations found NeuroSense performed well compared with standard testing in the laboratory and in a small number of intensive care patients. The project includes collaborators from University Medicine Rostock, the Massachusetts Institute of Technology, and Harvard Medical School. Next steps include adding an automated alarm to flag abnormal trends, conducting larger clinical studies, and refining components toward potential commercialization.

“This platform is designed to almost instantly capture trends and identify complications before they become much more serious,” said Dr. Mahla Poudineh, a professor of electrical and computer engineering and the Canada Research Chair in Health Monitoring BioNano Devices at Waterloo.

“The benefits include early warning of infection or drain malfunction, enabling faster, better treatment decisions,” said Fatemeh Keyvani, a Ph.D. student in electrical and computer engineering at Waterloo who led the research.

Related Links
University of Waterloo


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Urine Analyzer
respons® UDS100
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.